Quince Therapeutics, Inc. - Asset Resilience Ratio
Quince Therapeutics, Inc. (QNCX) has an Asset Resilience Ratio of 44.86% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Quince Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. Check Quince Therapeutics, Inc. strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Quince Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Quince Therapeutics, Inc. worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $11.94 Million | 44.86% |
| Total Liquid Assets | $11.94 Million | 44.86% |
Asset Resilience Insights
- Very High Liquidity: Quince Therapeutics, Inc. maintains exceptional liquid asset reserves at 44.86% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Quince Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Quince Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Quince Therapeutics, Inc. (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Quince Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 12.77% | $11.94 Million | $93.52 Million | -17.43pp |
| 2024-12-31 | 30.20% | $34.57 Million | $114.48 Million | +0.06pp |
| 2023-12-31 | 30.14% | $54.31 Million | $180.20 Million | -13.75pp |
| 2022-12-31 | 43.89% | $45.60 Million | $103.91 Million | +16.06pp |
| 2021-12-31 | 27.83% | $37.08 Million | $133.23 Million | -7.52pp |
| 2020-12-31 | 35.35% | $66.98 Million | $189.47 Million | -3.77pp |
| 2019-12-31 | 39.12% | $48.65 Million | $124.37 Million | -25.16pp |
| 2018-12-31 | 64.28% | $46.84 Million | $72.88 Million | -- |
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disord… Read more